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Background: The quality and safety of cell therapy products must be maintained throughout their production and
quality control cycle, ensuring their final use in the patient. We validated the Lymulus Amebocyte Lysate (LAL) test
and immunophenotype according to International Conference on Harmonization Q2 Guidelines and the EU
Pharmacopoeia, considering accuracy, precision, repeatability, linearity and range.
Methods: For the endotoxin test we used a kinetic chromogenic LAL test. As this is a limit test for the control of
impurities, in compliance with International Conference on Harmonization Q2 Guidelines and the EU
Pharmacopoeia, we evaluated the specificity and detection limit.
For the immunophenotype test, an identity test, we evaluated specificity through the Fluorescence Minus One
method and we repeated all experiments thrice to verify precision. The immunophenotype validation required a
performance qualification of the flow cytometer using two types of standard beads which have to be used daily to
check cytometer reproducibly set up. The results were compared together.
Collected data were statistically analyzed calculating mean, standard deviation and coefficient of variation
percentage (CV%).
Results: The LAL test is repeatable and specific. The spike recovery value of each sample was between 0.25 EU/ml
and 1 EU/ml with a CV% < 10%. The correlation coefficient (≥ 0.980) and CV% (< 10%) of the standard curve tested
in duplicate showed the test's linearity and a minimum detectable concentration value of 0.005 EU/ml.
The immunophenotype method performed thrice on our cell therapy products is specific and repeatable as
showed by CV% inter -experiment < 10%.
Conclusions: Our data demonstrated that validated analytical procedures are suitable as quality controls for the
batch release of cell therapy products.
Our paper could offer an important contribution for the scientific community in the field of CTPs, above all to small
Cell Factories such as ours, where it is not always possible to have CFR21 compliant software.
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The success of advanced therapy-based approaches is
highly dependent upon the development of standardized
protocols according to Good Manufacturing Practice
(GMP) [1], including production and quality control
processes.
The quality and safety of cell therapy products (CTP)
must be maintained throughout their production and
quality control (QC) cycle, ensuring their final use in the
patient. According to International Conference on Har-
monization Q2 (ICH Q2) Guidelines [2] and the European
(EU) Pharmacopoeia [3], the QC process should be
validated to confirm that the analytical procedure employed
for a specific test is suitable for its intended use. Results
from method validation can be used to judge the quality,
reliability and consistency of analytical results.
The four most common types of analytical methods, each
with its own set of validation requirements, are identity
tests, quantitative tests for impurity content, limit tests for
the control of impurities, potency tests.
The validity of an analytical method should be demon-
strated using samples or standards that are similar to
routinely analyzed unknown samples. The process should
follow a validation protocol, also considering instruments,
supplies and reagents.
The validation strategy described in the validation
protocol should clearly define the roles and responsi-
bilities of each step involved in the validation of analytical
methods.
The elements of the analytical method requiring proof
through validation as contained in the ICH Q2A guidelines
are specificity, accuracy, precision, repeatability, linearity
and range [2,4].
In this work, we report the validation processes of a
immunophenotype method as an identity test and Lymulus
Amebocyte Lysate (LAL) test as a limit test for the control
of impurities, as a conclusion of a validation process that
also including a potency test, as previously reported [5].
The LAL test is used to assess that CTPs given to
patients are negative for bacterial endotoxin, that is the
lipopolysaccharide (LPS) component of the cell wall of
Gram-negative bacteria. The pathological effects of endo-
toxin, when injected, are a rapid increase in core body
temperature followed by extremely rapid and severe
shock, often followed by death before the cause is even
diagnosed.
The principle aim of this assay is a reaction between
LPS and a lysate contained in amoebocyte cells derived
from the blood of Limulus Polyphemus [6]. The LAL in
presence of bacterial endotoxins activate an enzymatic
reaction that leads to a local blood coagulation cascade.
The immunophenotype analysis is a multiparametric
technique to identify cell subpopulations. Cells can be
identified on the bases of their size and by usingfluorescent monoclonal antibodies that bind to intra-
cellular and surface antigens. For CTPs, cell identity is a
fundamental parameter to be assessed in GMP quality
controls [7].
Using well-designed experiment and statistically relevant
analysis, method validation can be accomplished in
accordance with ICH guidelines [2]. Thus, to perform test
validation, we assessed a detailed validation protocol for
each test. For our study, we chose three cell populations
and respective supernatants: bone marrow mesenchymal
stem cells (BM MSCs) and Cytotoxic T Lymphocytes
(CTLs), both cell therapy products that we will produce,
in GMP conditions, for clinical trials of immunotherapy
and regenerative medicine, and dendritic cells (DCs) used
as antigen presenting cells (APCs) to generate CTLs.
Materials and methods
Cell source
BM MSCs isolation and expansion
BM MSCs were isolated from humans obtained by aspir-
ation from the posterior iliac crest of healthy donors after
written informed consent. The frequency BM MSC was
about 1/104 cells [8]. Briefly, whole bone marrow (wBM)
was seeded at a density of 100,000/cm2 in Mesenchymal
Stem Cell Growth Medium (MesenCult® Proliferation Kit;
Human, Stemcell technologies, Vancouver, BC, Canada)
containing 10% of fetal bovine serum (FBS) in 75 or
150 cm2 T-flasks and maintained at 37°C with an atmos-
phere of 5% CO2. After 5 days, the non-adherent cells were
removed and re-feed every 3–4 days; at confluence, they
were detached, and re-plated at different densities for one
to four passages [9].
To perform immunophenotype analysis BM MSCs, at
the end of culture when confluent, were detached,
washed with Phosphate Buffered Saline (PBS) 1X (200 g
for 10 minutes) and resuspended in PBS 1X. BM MSCs
and supernatant at different dilutions were tested for
endotoxins.
PBMCs isolation
Peripheral blood mononuclear cells (PBMCs) were pre-
pared from buffy coats obtained from healthy donors
kindly provided by the local blood bank after informed
consent. PBMCs were layered on Hystopaque (Sigma
Aldrich, Milan, Italy) gradient (1.077 g/ml density). The
cells were centrifuged at 400 g for 30 minutes. The cells
in the interphase were collected and washed twice with
PBS 1X (200 g for 10 minutes).
Dendritic cells (DCs) generation
Dendritic cells (DCs) were generated from PBMCs after
adhesion for two hours at 37°C with an atmosphere of 5%
CO2. After two hours, the non-adherent cells were removed
and the adherent cells were cultured in CellGro DC
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with recombinant human (rh) granulocyte-macrophage
colony-stimulating factor (rhGM-CSF; CellGenix) and rh
Interleukin (IL)-4 (CellGenix) [10-12]. Fresh cytokines
were added on day 3. On day 5, adherent cells were matu-
rated with a cytochine cocktail for 48 hours: rhGM-CSF,
rhIL-4, rh-IL-6 (CellGenix), rhIL-1β (CellGenix), rh
Tumor Necrosis Factor-alpha (TNF-α; Cell Genix), rh
Prostaglandin E2 (PGE2; Cayman Chemical, Ann Arbor,
MI, USA).
On day 5 and on day 7, immature DCs (iDCs) and mature
DCs (mDCs) were immunophenotyped respectively.
Cytotoxic T Lymphocyte (CTLs) generation and expansion
PBMCs cells obtained were co-cultured with mDCs loaded
with irradiated human osteosarcoma cell lines SJSA1
derived from American Type Culture Collection (ATCC,
Rockville, MD, USA,) (ratio 1:10) in CellGro Serum-Free
Stem Cell Growth medium (SCGM; CellGenix) with 5%
Human Serum (HS; Lonza, Verviers, Belgium) supple-
mented with recombinant human Interleukin-7 (rhIL-7;
CellGenix), recombinant human Interleukin-12 (rhIL-12;Figure 1 LAL test validation protocol flow-chart. The test was performe
manager on the same samples (CTPs, CTPs supernatant, pyrogen-free wate
the detection limit. To evaluate accuracy, the assay includes seeding each s
endotoxin unit EU/mL was used. The acceptance criteria were: spike recove
with CV < 10% and correlation coefficient ≥ 0.980.CellGenix) and recombinant human Interleukin-15 (rhIL-15;
CellGenix) for seven days.
On day 7 the CTLs were re-stimulated with fresh DCs
obtained after PBMC adhesion, as explained above, loaded
with irradiated human osteosarcoma cell lines in SCGM
Medium with 5% HS supplemented with rhIL-2 and rhIL-15
for seven days.
CTLs stimulated cells were expanded in an antigen
independent manner [13] by co-culture with irradiated
autologous PBMCs in SCGM with 5% HS supplemented
with rhIL-2 and Muromonab-CD3 (OKT3; Milteny,
Bergisch Gladbach, Germany) for 7 days. After expansion
CTLs immunophenotyping was performed after washing
with PBS 1X (200 g for 10 minutes).
CTLs and supernatant at different dilutions were tested
for endotoxins.
Endotoxin test
LAL assay is a quantitative method to detect Gram - de-
rived endotoxin in a solution. LAL is an aqueous extract
of blood cells (amebocytes) from the "horseshoe crab",
Limulus Polyphemus. The endotoxin catalyzes thed three times under the same operating conditions by the QC
r) to test precision. According to ICH Q2 we evaluated specificity and
ample in duplicate. For linearity, a standard curve with 0.005
ry between 0.25 EU/ml – 1 EU/ml with a CV% < 10, standard curve
Table 1 LAL test: list of samples analyzed
Sample number Samples
1 PYROGEN-FREE WATER
2 SN + 10%FBS 1:10
3 SN + 10%FBS 1:50
4 SN + 10%FBS 1:80
5 SN + 10%FBS THAWED 1: 10
6 SN + 10%FBS THAWED 1:50
7 SN + 10%FBS THAWED 1:80
8 SN + 10%FBS HEATED 1:10
9 SN + 10%FBS HEATED 1:50
10 SN + 10%FBS HEATED 1:80
11 FS + 5%ALBUMIN 1:10
12 FS + 5%ALBUMIN 1:50
13 FS + 5%ALBUMIN 1:80
14 BM MSCs 1X103 cells/ml
15 BM MSCs 1X102 cells/ml
16 CTLs 1X103 cells/ml
17 CTLs 1X102 cells/ml
18 SN + 5%HS 1:10
19 SN + 5%HS 1:50
20 SN + 5%HS 1:80
21 SN + 5%HS THAWED 1:10
22 SN + 5%HS THAWED 1:50
23 SN + 5%HS THAWED 1:80
The test was performed on supernatant at different dilutions, on CTPs at
different concentrations, and on pyrogen-free water as negative control.
Abbreviations: SN supernatant, FBS fetal bovine serum, FS saline, HS
human serum.
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depends on the concentration of endotoxin present. The
activated enzyme is able to break the p-NitroAniline
(pNA) bond with the colorless artificial substrate. The
pNA released produces a yellow element quantitatively
photometrically determinable at 405 nm. The time required
before the appearance of a yellow color (reaction time)
is inversely proportional to the amount of endotoxin
present. The concentration of endotoxin in a sample is
calculated from its reaction time compared to the reaction
time of solutions containing known amounts of endotoxin
standard.
To detect the Gram - bacterial endotoxin on our CTPs,
we used the LAL Kinetic-K-QLC kit (Lonza). Standard
curve with 0.005 endotoxin unit EU/mL was used in this
assay. The high and low points in a valid standard curve
determine the lower and upper levels of endotoxin that
can be detected. The correlation coefficient (CC) of the
calculated standard curve should be ≥ 0.980. The assay
was assessed on 100 μL supernatant by incubating the
samples and the calibrators at 37°C in the presence of the
LAL for 1 hour and 40 minutes in a microplate reader
ELX −808 (Lonza).
The endotoxin test is a limit test for the control of
impurities, in compliance with ICHQ2 guidelines [2] and
the EU Pharmacopoeia [3], so, we evaluated specificity
and detection limit.
The endotoxin test validation protocol was performed
as shown in the flow chart (Figure 1).
The test was performed on supernatant at different
dilutions, on CTPs at different concentrations, and on
pyrogen-free water as negative control. For this analysis
we tested the supernatants containing FBS and HS,
added as explain above, to BM MSCs and CTLs culture
medium and those composed of saline (FS) and albumin
as a medium for the infusion of cell therapy products in
the patient. The CTP’s supernatant was diluted in LAL
Reagent Water (Lonza) considering the maximum valid
dilution (MVD) equal to 100. To exclude the possibility of
false negatives, we validated the freezing of the supernatant
by running the test on the supernatant fresh and thawed.
We also performed the test on the supernatant heated
to 75°C to exclude the effect of trypsin, which can give
interference (Table 1). All the tubes, water and pipette-tips
were certified pyrogen-free.
To verify precision, the LAL test was performed three
times under the same operating conditions by quality
control (QC) manager on the same samples.
To evaluate assay accuracy, the test includes seeding
each sample in duplicate.
Each sample must be accompanied by a positive product
control (PPC) that is a sample of product to which a
known amount of endotoxin (0.5 EU/ml) has been added.
To verify test specificity, that is the ability to detect theanalyte in the presence of interfering substances, we
evaluated the spike recovery (the amount of endotoxin
recovered) for each sample.
Immunophenotyping analysis
The immunophenotype validation protocol (Figure 2)
required a first step which is the titration of each antibody
performed by using scalar antibody dilution. The better
antibody concentration was that with higher resolution
index, that is a greater separation between the negative
control peaks and the labeled samples.
A second step was Performance Qualification (PQ), in
compliance with ICHQ2 [2], that demonstrates that the
process or equipment performs as intended in a consistent
manner over time. The resolution index was calculated as
follows: IR = Xi-X0/√ SDi
2 + SD0
2 where Xi is the mean
fluorescence intensity (MFI) of the positive cell population,
X0 is the mean fluorescence intensity of the negative
cell population, SDi is the MFI standard deviation of
the positive cell population and SD0 is the MFI standard
deviation of the negative cell population. We carried out
Figure 2 Immunophenotype validation protocol flow-chart. The immunophenotype validation protocol required: a first step which is the
titration of each antibody performed by using scalar antibody dilution; a second step, named Performance Qualification (PQ), during which the
QC manager used two types of standard beads to check cytometer reproducibly over time. Immunophenotyping analysis is an identity test to
evaluate specificity by using FMO method. The test was performed three times to test precision. The acceptance criteria were: inter-experiment
CV% ≤ 10%, BM MSCs positive for CD90, CD73, CD105 and negative for CD45, CD14, CD34, CD19 and HLADR; mDCs positive for CD80, CD86,
CD83, CD40, CD11c and HLADR at a high level; CTLs positive for CD3+, CD3 + CD4+, CD3 + CD8+, CD56 + CD3- at a low level and negative
for CD19.
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in different panels as described below: CD45- fluorescein
isothiocyanate (FITC), CD34-FITC, CD14-FITC, HLADR-
phycoerythrin (PE), CD19–allophycocyanin (APC), CD90-
FITC, CD73-PE, CD83-FITC, CD40-PE, CD80-FITC,
CD86-PE, CD11c-APC, HLADR- peridinin-chlorophyll
protein cyanine 5.5 (PerCP-Cy5.5), CD45RA FITC/
CD45RO PE/CD3 PercP/CD8 APC, CD45RA FITC/
CD45RO PE/CD3 PercP/CD4 APC, CD3 FITC/CD8
PE/CD4 APC/CD45 PercP, CD3 FITC/CD56-16 PE/
CD19 APC/CD45 PercP (Becton Dickinson), CD105-APC
(Miltenyi Biotech).
To perform PQ, the QC Manager, over five consecu-
tive days used BD FACS 7-Color Setup Beads (Becton
Dickinson, San Jose, CA, USA) and CS&T beads (Becton
Dickinson), two types of standard beads which have tobe used daily to check cytometer reproducibly set up.
We checked our Levey Jennings graph of each type of bead
in order to evaluate time trend. The results obtained from
both beads were compared together.
As the immunophenotype analysis, in compliance with
ICHQ2 [2] guidelines and the EU Pharmacopoeia [3], is
an identity test, we evaluated specificity.
We tested specificity on BM MSCs, iDCs, mDCs and
CTLs, by using Fluorescence Minus One method (FMO):
each cell population was stained with all the reagents,
except one, at a time, in order to verify whether in the
absence of one antibody, the labeled cells were negative
for the removed one.
BM MSCs were labeled with the following mAb panels :
anti-human CD45–CD34-CD14-FITC/ HLADR-PE/ CD19–
APC, CD90-FITC/ CD73-PE/ CD105-APC.
Table 2 LAL test precision
Sample
number
Experiment 1
(EU/ml)
Experiment 2
(EU/ml)
Experiment 3
(EU/ml)
1 <0.0050 <0.0050 <0.0050
2 <0.0050 <0.0050 <0.0050
3 <0.2500 <0.2500 <0.2500
4 <0.4000 <0.4000 <0.4000
5 <0.0500 <0.0500 <0.0500
6 <0.2500 <0.2500 <0.2500
7 <0.4000 <0.4000 <0.4000
8 <0.0500 <0.0500 <0.0500
9 <0.2500 <0.2500 <0.2500
10 <0.4000 <0.4000 <0.4000
11 <0.0500 <0.0500 <0.0500
12 <0.2500 <0.2500 <0.2500
13 <0.4000 <0.4000 <0.4000
14 <0.0050 <0.0050 <0.0050
15 <0.0050 <0.0050 <0.0050
16 <0.0050 <0.0050 0.0627
17 <0.0050 <0.0050 <0.0050
18 0.0667 0.0558 <0.0500
19 <0.2500 <0.2500 <0.2500
20 0.4095 <0.4000 <0.4000
21 <0.0500 <0.0500 0.065
22 <0.2500 <0.2500 <0.2500
23 <0.4000 <0.4000 <0.4000
The LAL test was performed three times under the same operating conditions
by the QC manager on our CTPs and supernatants. The test was repeatable.
Endotoxin concentrations in all samples (EU/ml) were ≤ 0.5 EU/ml as requested
by the Food and Drug Administration. Samples analysed are given in Table 1.
Samples: 1 = pyrogen free water (negative control); 2–10 = supernatants with
FBS; 11–13 = supernatants with albumin; 14–17 = CTPs; 18–23 = supernatants
with HS.
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CD83-FITC/ CD40-PE/ HLADR PerCP-Cy5.5/ CD11c-
APC, CD80-FITC/ CD86-PE HLADR- PerCP-Cy5.5,
CD11c-APC.
CTLs immunophenotyping was performed with the
following mAbs panels: anti human CD3 FITC/CD8 PE/
CD4 APC/CD45 PercP, CD3 FITC/CD56-16 PE/CD19
APC/CD45 PercP. CTL effectors were labeled with anti-
human CD45RA FITC/CD45RO PE/CD3 PercP/CD8
APC, CD45RA FITC/CD45RO PE/CD3 PercP/CD4 APC.
For each antibody panel, 500,000 cells/100 μl were
stained for 20 minutes.
The labeled cells were thoroughly washed with PBS 1×
(200 g for 10 minutes) and analyzed on a FACSCanto II
(Becton Dickinson) with the DIVA software program.
The percentage of positive cells was calculated using
the FMO cells as a negative control for each antigen
expression.
To test inter-experiment repeatability all immuno-
phenotyping tests on our CTPs were repeated three
times by the QC Manager.
Data analysis and statistical approach
The endotoxin test result was considered valid when the
spike recovery was between 0.25 EU/ml – 1 EU/ml with
a CV% less than 10%, a standard curve with CV% less
than 10% and a correlation coefficient ≥ 0.980.
To test the precision of the immunophenotype ana-
lysis, we calculated mean, SD and CV% of the Mean
Fluorescence Intensity (MFI) of each marker considering
the results of triplicate experiments.
The immunophenotype method was considered specific
when: BM MSCs were positive (≥ 70%) for CD90, CD73,
CD105 and negative (≤ 2%) for CD45, CD14, CD34, CD19
and HLADR [14]; mDCs expressed high levels express
high levels of CD80, CD86, CD83, CD40, CD11c and
HLADR [12], some of which were upregulated compared
to iDC; CTLs expressed for CD3+ (≥ 70%), CD3 +CD4+,
CD3 +CD8+ (≥ 30%), negative for CD19 and expressed
low levels of CD56 + CD3- (≤ 10%) [15].
Equipment validation
Microplates reader ELX-808 (Lonza) and flow cytometer
FACS Canto II (Becton Dickinson) were properly quali-
fied by Installation Qualification (IQ) and Operational
Qualification (OQ) according to GMP guidelines [1,2].
Micropipettes used for the tests were calibrated by the
manufacturer. Furthermore a new set of pipettes every
year is bought, as we considered them critical instruments
in risk assessment.
Statement of ethical approval
Bone Marrow (BM) and peripheral blood (PB) were
obtained from healthy donors after written informedconsent in accordance with the approval of the Ethics
Committees, of the Regina Margherita, S.Anna and
Mauriziano hospitals, and in compliance with the Helsinki
Declaration.
Results
Endotoxin test
As previously explained, the assay was performed on our
CTPs and supernatants using a kinetic chromogenic
method. The test performed three times, under the same
operating conditions by the QC Manager was repeatable
(Table 2). Endotoxin concentrations in all samples were
less than 0.5 EU/ml as requested by the Food and Drug
Administration. The endotoxin limit for all parenteral
drugs is 5 EU/Kg and for those that have an intrathecal
route of administration is 0.2 EU/Kg [16]. For all tests
the absolute value of CC of the standard curve tested in
duplicate was ≥ 0.980 and the CV% less than 10%
Rustichelli et al. Journal of Translational Medicine 2013, 11:197 Page 7 of 13
http://www.translational-medicine.com/content/11/1/197showed the test’s linearity. The minimum detectable
concentration was 0.005 EU/ml.
Pyrogen-free water used as a negative control, had an
endotoxin value less than the lowest standard according
to the European Pharmacopeia [3].
As suggested by ICHQ2 [2] we demonstrated the
discrimination of the analyte in the presence of impurities
by spiking all samples with known levels of endotoxin and
by comparing the results obtained on un-spiked samples.
According to acceptance criteria the mean spike recovery
of three replicates for all samples analyzed, was between
0.25 EU/ml and 1 EU/ml with PPC CV% less than 10.
These data summarized in Figure 3A and B demonstrated
the test’s specificity.
Immunophenotyping analysis
The first step of our analysis was the titration of each
monoclonal antibody to be used for the immuno-
phenotype of our CTPs. The determination of the antibodyFigure 3 LAL test specificity. According to the acceptance criteria, the hi
samples analysed was between 0.25 EU/ml and 1EU/ml (A) with PPC CV%
Samples: 1 = pyrogen free water (negative control); 2–10 = supernatants wi
18–23 = supernatants with HS.dilution constitutes the previous key step to flow cytometry
analysis, since it is highly dependent on the antigen density
in the cells. Ideally, each antibody concentration should be
established for each sample that requires analysis [17]. To
label the cell populations we chose the concentration of
each antibody with the highest resolution index. The lowest
antibody concentration was chosen when there was an
equal resolution index (Table 3). Figure 4 is a representative
panel of antibody titration.
As a second step, we performed Performance Quali-
fication (PQ), as explained above, in compliance with
ICHQ2 [2]. We evaluated the time trend for five
consecutive days for each type of bead and we verified
the stability over time of the cytometer set up (data not
shown).
According to ICHQ2 [2] guidelines and the EU
Pharmacopoeia [3] we evaluated specificity on BM MSCs,
iDCs, mDCs and CTLs, as described above, and shown by
representative panel of BM MSCs in Figure 5.stogram shows that the mean spike recovery of three replicates for all
less than 10 (B). Bars are SD. Samples analysed are given in Table 1.
th FBS; 11–13 = supernatants with albumin; 14–17 = CTPs;
Table 3 Antibody tritation
Markers Antibody concentration (μl)
5 10 20 40 80
CD45 FITC 2.0 2.0 2.0 1.9 1.9
CD34 FITC 1.8 1.9 2.0 1.9 1.9
CD14 FITC 1.9 1.9 1.9 1.9 1.9
HLADR PE 0.8 0.7 0.7 0.8 0.9
CD73 PE 1.8 1.9 2.0 2.0 2.1
CD83 FITC 1.7 1.8 1.8 1.9 2.0
CD40 PE 1.5 1.7 1.6 1.7 1.8
CD80 FITC 1.9 1.9 1.9 1.9 2.0
CD86 PE 1.1 1.1 1.1 1.2 1.5
HLADR PercPCy5.5 1.2 1.2 1.3 1.2 1.3
CD45RA FITC/CD45RO PE/CD3 PercP/CD8 APC 1.7 1.9 1.5 1.5 1.7
CD45RA FITC/CD45RO PE/CD3 PercP/CD8 APC 2.6 3.0 2.5 2.0 2.2
CD45RA FITC/CD45RO PE/CD3 PercP/CD8 APC 2.5 2.5 2.5 1.9 2.1
CD45RA FITC/CD45RO PE/CD3 PercP/CD8 APC 2.4 3.3 2.6 2.5 1.7
CD45RA FITC/CD45RO PE/CD3 PercP/CD4 APC 1.8 1.7 1.4 1.3 1.4
CD45RA FITC/CD45RO PE/CD3 PercP/CD4 APC 2.2 2.1 2.2 2.2 2.1
CD45RA FITC/CD45RO PE/CD3 PercP/CD4 APC 2.5 2.4 2.4 2.2 2.1
CD45RA FITC/CD45RO PE/CD3 PercP/CD4 APC 5.1 5.0 4.5 4.6 4.5
CD3 FITC/CD8 PE/CD4 APC/CD45 PercP 2.2 2.0 2.0 2.0 1.9
CD3 FITC/CD8 PE/CD4 APC/CD45 PercP 2.6 1.8 1.8 1.2 1.2
CD3 FITC/CD8 PE/CD4 APC/CD45 PercP 4.3 4.2 4.0 4.0 4.0
CD3 FITC/CD8 PE/CD4 APC/CD45 PercP 4.0 3.9 3.8 3.7 3.6
CD3 FITC/CD56-16 PE/CD19 APC/CD45 PercP 2.1 2.4 2.4 2.3 2.1
CD3 FITC/CD56-16 PE/CD19 APC/CD45 PercP 0.9 1.2 1.6 1.2 1.1
CD3 FITC/CD56-16 PE/CD19 APC/CD45 PercP 2.8 1.8 3.4 2.4 1.9
CD3 FITC/CD56-16 PE/CD19 APC/CD45 PercP 3.1 3.3 3.7 3.7 3.7
Markers Antibody concentration (μl)
2 5 10 20 40
CD105 APC 1.8 1.8 1.8 1.8 1.8
CD90 FITC 1.8 1.8 1.9 1.9 1.8
Markers Antibody concentration (μl)
1 2 5 10 20
CD11c APC 1.6 1.4 1.3 1.4 1.4
CD19 APC 2.3 2.8 2.9 2.7 2.4
The immunophenotype validation required a first step which is the tritration of each antibody performed by using scalar antibody dilution. The best
antibody concentration was that with a higher resolution index. The lowest antibody concentration was chosen when there was an equal
resolution index.
Rustichelli et al. Journal of Translational Medicine 2013, 11:197 Page 8 of 13
http://www.translational-medicine.com/content/11/1/197BM MSCs were negative for CD45, CD14, CD34
hematopoietic surface antigens, CD19 B lymphocyte
antigen and HLADR not expressed on mesenchymal
stem cells in an unstimulated state. BM MSCs expressed
high levels of CD90 (mean 99.2% ± 0.31), CD73 (mean
99.4% ± 0.27), CD105 (mean 98.9% ± 0.21) (Figure 6A).
DCs were selected from PBMCs using an adhesion
method and cultured in specific medium with rhGM-CSF[11] and rhIL-4 [10]. After 5 days of culture iDCs expressed
a low level of CD83 (mean 16.6% ± 3.31), CD86 (50.8%±
9.95) and a high level of CD11c (mean 98.7% ± 0.50) and
HLADR (mean 99.1% ± 0.41), but not CD40 and CD80
(Figure 6B). The mDCs expressed a high level of CD83 (mean
99.3% ± 0.30), CD86 (mean 96.3% ± 1.26), CD40 (mean
97.4% ± 2.06), CD80 (mean 95.7% ± 1.65), HLADR (mean
99% ± 0.40) and CD11c (mean 98.8% ± 0.56) (Figure 6B).
Figure 4 Representative panel of antibody titration. CD90 FITC
titration on BM MSCs.
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were stimulated with mDCs pulsed with irradiated human
osteosarcoma cell lines, used as the source of tumor Ag.
CTLs were expanded in an Ag-independent way with
rhIL-2 and OKT3.
After at least 7 days of Ag-independent expansion,
we obtained the following populations: CD3+ (mean
86.2% ± 3.80), CD3 +CD8+ (mean 30.3% ± 3.43), CD3 +
CD4+ (mean 38%± 3.23), CD45RO+CD4+ (mean 33.4%±
5.08), CD45RO + CD8+ (mean 30.7% ± 3.77), CD56 +
CD3- (mean 6.2% ± 0.70). The lymphocyte population was
negative for CD45RA and CD19 (Figure 6C).
As previously explained, the immunophenotype test
was performed on our CTPs three times by the sameFigure 5 Representative panel of fluorescence minus one method (FMoperator. To obtain the inter experiment CV% QC manager
calculated the mean and SD of the MFI of three replicates
for each cell type (BM MSCs, CTLs, mDCs, iDCs) for
each marker. For each marker, the inter experiment CV%
was ≤ 10%. All the data are summarized in Table 4. These
data demonstrated that the method is both valid and
precise.
Discussion
Cellular therapy is an emerging field in medicine. All the
cell medicinal products must be produced in compliance
with current GMP guidelines for medicinal products
and investigational medicinal products for human use
[7,18-24]. During CTP manufacturing, critical steps
should be considered to demonstrate their suitability
for routine processing and should be validated in order
to produce cells of the required quality. All biological
products must meet the prescribed requirements and
no lot of any licensed product may be released by the
manufacturer prior to the completion of tests for the
conformity with standards applicable to such products
[25]. In order to guarantee sterility, in accordance with
international guidelines [7], one of the parameters that
needs to be monitored in the manufacturing phases
and in lot release is the endotoxin level. The LAL test is
used to rule out that the products, given to patients, will
cause toxic reactions, resulting from pyrogen contamin-
ation. On these bases, we have successfully validated, in
compliance with the EU Pharmacopeia [3], endotoxin
testing of BM MSCs and CTLs as cell therapy products.O). Cytofluormetric analysis of BM MSCs using FMO.
Figure 6 Immunophenotype specificity. The histograms show the mean percentage expression of three experiments of each marker for BM
MSCs (A), iDCs (B-light grey histograms), mDCs (B-dark grey histograms) (B) and CTLs (C). Bars are SD.
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compliance with ICHQ2 [2], we demonstrated that the
endotoxin chromogenic method, validated in accordance
with the EU Pharmacopoeia [3], is suitable as a release
test for our CTPs.
Although Soncin at al. [25] demonstrated the possible
use of an alternative method for endotoxin evaluation in
cell based products, for our purposes, we chose to validate
the endotoxin test, a traditional method, that has been
both widely used in the pharmaceutical industry and
suggested by the EU Pharmacopeia.
For the batch release of CTPs used in clinical protocols,
to satisfy pharmaceutical quality requirements [7] for
cell identity determination, the immunophenotype is a
fundamental parameter to be assessed.
On the basis of our previous pre-clinical papers on
BM MSCs, DCs and CTLs reporting the characterization of
the cell identity and to data published by other authors in
this field [9,12,13,26,27], the aim of our work was simply to
validate the analytical procedure of immunophenotyping,
according to European Parmacopoeia [3] and ICHQ2 [2],
on our CTPs and not to assay cell potency. Furthermore,
we referred to the above described data, using cellsprepared in the same way, as robust data to set up, in our
Validation Master Plan, the acceptance criteria of the
identity of every cell type analysed.
According to ICHQ2 for immunophenotyping, which
is an identity assay, we tested specificity by FMO. In
the present study we have demonstrated that the
immunophenotype test is validated according to the
current rules in the cell therapy field as it is able to
discriminate the populations of interest.
The immunophenotype method for BM MSCs charac-
terisation was considered specific as they expressed high
level of CD90, CD73, CD105 and were negative for CD45,
CD14, CD34, CD19 and HLADR and moreover they were
able to adhere to the plastic in standard culture conditions
and to differentiate into osteoblasts, adypocytes, and chon-
drocytes [8] (data not shown), in compliance with the
International Society for Cellular Therapy (ISCT) guide-
lines, that specify the minimal criteria to define human
MSCs [14].
We also analysed DCs, which are used as antigen
presenting cells (APCs) [26-28] for the in vitro generation
of tumor specific CTLs. The immunophenotyping was
specific as iDC expressed a low level of CD83, CD86, a
Table 4 Immunophenotype precision
BM MSCs Markers CV% Inter-experiment
CD90 FITC 6.22
CD73 PE 0.95
CD105 APC 1.86
CD45-34-14 FITC 3.13
HLADR PE 4.46
CD19 APC 3.84
iDCs Markers CV% Inter-experiment
CD83 FITC 2.2
CD40 PE 10
HLADR PERCPCY5 4.6
CD11c APC 2.7
CD80 FITC 8.4
CD86 PE 7.1
mDCs Markers CV% Inter-experiment
CD83 FITC 3.6
CD40 PE 7.9
HLADR PERCPCY5 6.3
CD11c APC 5.4
CD80 FITC 5.1
CD86 PE 3.9
CTL-LS Markers CV% Inter-experiment
CD3 FITC 9.7
CD8 PE 10
CD4 APC 8.1
CD45 PERCP 8.1
CD56 PE 7.0
CD19 APC 8.0
CTL-E Markers CV% Inter-experiment
CD45RA FITC 9.4
CD45RO PE 10
CD4 APC 3.7
CD3 PERCP 6.9
CD8 APC 6.4
The immunophenotype test was performed three times under the same
operating conditions by the same operator on our CTPs. The inter experiment
CV% was calculated considering the mean and SD of the mean fluorescence
intensity (MFI) of each cytofluorimetric marker.
The acceptance criteria was an inter-experiment CV% ≤ 10%.
Abbreviations: CTL LS Cytotoxic T Lymphocyte subpopulations, CTL E Cytotoxic
T Lymphocyte effectors.
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and CD80. In contrast the mDCs, after a maturation step
with a cytokine cocktail, showed the up-regulation of
co-stimulatory molecules that are crucial in determining
whether engaged T lymphocytes become anergic or develop
productive immunity [29]. Furthermore, the fact that
CD83, one of the best-known maturation markers for
human dendritic cells, is strongly up-regulated togetherwith co-stimulatory molecules such as CD80 and CD86
during DC maturation suggests it plays an important role
in immune responses induction [30].
The protocol used to generate anti-tumor CTLs includes
two rounds of tumor-specific stimulation followed by an
Ag-independent expansion [13]. Flow cytometry analysis of
CTLs was specific as they were positive for CD3+, CD3 +
CD8+, CD3 +CD4+, negative for CD19 and expressed low
level of CD56 + CD3-, according to our acceptance criteria,
and in addition they were able to kill specific target (data
not shown). Our data are in agreement with those which
show that CD4+ T cells are also involved in anti–tumor
effector activity through a perforin-mediated mechanism
[15]. Their results supported the central role played by
CD4+ T cells not only in providing help for optimal
priming and expansion of anti-tumor CD8+ T cells, but
also as active effectors of the immune response [31,32].
Furthermore, according to published data reporting that
the expression of CD45 isoforms in human T cell distin-
guishes naïve T cells (CD45RA+) from memory (CD45RO+)
T cells [33], the phenotypic analysis of our CTLs showed
CD45RO + cells in both CD4 and CD8 subsets and were
negative for CD45RA. Recent studies indicate that
memory T Lymphocytes contain distinct populations of
central memory (TCM) and Effector Memory (TEM)
cells characterized by distinct homing capacity and effector
function [34].
Although accuracy, repeatability or detection limits are
not required for identity test validation, we did, however,
decide, to verify precision of every CTPs by performing
immunophenotype staining and analysis of only one sample
in triplicate and work out the inter experiment CV%.
The LAL test is instead a limit test for the control of
impurities and, for PQ assessment, specificity and detection
limit validation are required under ICHQ2. Moreover,
PE gives a good description of the LAL test in terms of
accuracy, linearity, detection limit and specificity by
seeding each sample in duplicate, using a standard curve
and spike recovery, respectively. We followed these require-
ments to reach the task, carrying out the test in triplicate
on the same samples.
Our validation policy in this context was due to the
fact that the software used to this purpose is not CFR21
compliant [35-37]. So, in order to ensure our validation
results, we decided to validate only the QC Manager
performing tests in triplicate on the same samples. The
future role of the QC Manager will be the training of the
other Qualified Operators (QOps).
Conclusions
In conclusion, according to ICH guidelines [2], this
validation protocol showed that analytical methods for
endotoxin and immunophenotype analysis may be used
as quality controls for the batch release of CTPs,
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clinical cell-based protocols.
Thanks to the data present in this study, together
with those previously described by Gunetti et al. [5] we
demonstrated the feasibility of the validation of analytical
methods for cell therapy products; and thus our paper
could offer an important contribution for the scientific
community in the field of CTPs, above all to small Cell
Factories such as ours, if it is not always possible to have
CFR21 compliant software.
Abbreviations
APC: Allophycocyanin; APCs: Antigen presenting cells; BM MSCs: Bone
marrow mesenchymal stem cells; CC: Correlation coefficient; CTLs: Cytotoxic
T lymphocytes; CTP: Advanced therapy products; CV%: Coefficient of
variation percentage; DCs: Dendritic cells; EU: Endotoxin unit; EU
Pharmacopoeia: (EU) Pharmacopoeia; FBS: Fetal bovine serum;
FITC: Fluorescein isothiocyanate; FMO: Fluorescence minus one; GMP: Good
manufacturing practice; GM-CSF: Granulocyte-macrophage colony-
stimulating factor; HS: Human serum; ICH Q2: International conference on
harmonization Q2; IL: Interleukin; IQ: Installation qualification; iDCs: Immature
dendritic cells; LAL: Limulus amebocyte lysate; LPS: Lipopolysaccharide;
mAb: Monoclonal antibodies; mDCs: Mature dendritic cells; MFI: Mean
fluorescence intensity; OQ: Operational qualification; PBS: Phosphate buffer
saline; PBMCs: Peripheral blood mononuclear cells; PE: Phycoerythrin; PerCP-
Cy5.5: Peridinin-chlorophyll protein cyanine 5.5; PerCP: Peridinin-chlorophyll
protein; PGE2: Prostaglandin E2; PPC: Positive product control;
PQ: Performance qualification; QC: Quality control; QOps: Qualified operators;
SD: Standard deviation; TNF: Tumor necrosis factor; VMP: Validation master
plan; wBM: Whole bone marrow.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
DR participated in the design of the study, carried out the experiment,
acquired/ analyzed /interpreted data, performed the statistical analysis, and
drafted the article. SC participated in the design of the study, analyzed/
interpreted data, and performed the statistical analysis. MG participated in
the design of the study, interpreted data, and performed the statistical
analysis. KM participated in the design of the study, interpreted data, and
performed the statistical analysis. ES participated in the design of the study,
carried out the cell biology studies, interpreted data, and performed the
statistical analysis. MM participated in the design of the study, interpreted
data, and performed the statistical analysis. LC participated in the design of
the study, interpreted data, and performed the statistical analysis. FS
participated in the design of the study, interpreted data, and performed the
statistical analysis. ML participated in the design of the study, interpreted
data, and performed the statistical analysis. IF conceived of the study,
participated in the design of the study, interpreted data, drafted the article
FF conceived of the study, contributed reagents/materials/analysis tools and
interpreted data. All authors revised the article critically for important
intellectual content, read and approved the final manuscript.
Authors’ information
DR: MSc, Head, Quality Control.
SC: PhD, Qualified Operator, Production.
MG: PhD, Qualified Operator, Quality Control.
KM: BSc, Head, Production.
ES: PhD, Qualified Operator, Production.
MM: PhD, Qualified Operator, Production.
FS: DipBiol, , Qualified Operator, Production.
ML: DipBiol, , Qualified Operator, Quality Control.
LC: PhD, Qualified Operator, Quality Control.
IF: MSc, Qualified Person, Quality Assurance.
FF: MD, Director.Acknowledgments
We are grateful to Chiara Ferrandi and Vittoria Ardissone (PROCELLTECH S.r.l)
for regulatory and technical support and advice in experimental design. We
also are grateful to Alessandra Mandese for data management and to
Andrew Martin Garvey for editorial assistance. This work was partially
supported by Rete Oncologica del Piemonte e della Valle d’Aosta network
and Compagnia di San Paolo Foundation, Turin.
Author details
1Paediatric Onco-Hematology, Stem Cell Transplantation and Cellular
Therapy Division, City of Science and Health of Turin, Regina Margherita
Children’s Hospital, P.zza Polonia 94, Turin 10126, Italy. 2Department of Public
Health and Paediatrics, University of Turin, P.zza Polonia 94, 10126, Turin,
Italy.
Received: 28 February 2013 Accepted: 21 August 2013
Published: 27 August 2013References
1. EudraLex: The Rules Governing Medicinal Products in the European
Union, Volume 4, Good Manufacturing Practice, Medicinal Products for
Human and Veterinary Use. Ann Rev Mar Sci 2001, 15.
2. International conference on the harmonization of technical requirements
for the registration of pharmaceuticals for human use: ICH harmonized
tripartite guideline validation of analytical procedures: text and methodology
Q2 (R1).Current Step 4 version, Parent Guideline dated 27 October 1994
(Complementary Guideline on Methodology dated 6 November 1996
incorporated in November; 2005.
3. European P: European Directorate for the Quality of Medicines & HealthCare
(EDQM). 7th edition; 2011.
4. S.W: Analytical Methods: A Statistical Perspective on the ICH Q2A and
Q2B Guidelines for Validation of Analytical Methods. BioPharm
International 2006.
5. Gunetti M, Castiglia S, Rustichelli D, Mareschi K, Sanavio F, Muraro M,
Signorino E, Castello L, Ferrero I, Fagioli F: Validation of analytical methods
in GMP: the disposable Fast Read 102(R) device, an alternative practical
approach for cell counting. J Transl Med 2012, 10:112.
6. Sandle T: Pyrogens Endotoxin and the LAL test: An Introduction in
Relation to Pharmaceutical Processing. GBPR 2012. Inc. May 2012
Newsletter, Evelyn Heitman Editor.
7. Committee for Human Medicinal Products (CHMP): Guidelines on Human
Cell-Based Medicinal Products. London: European Medicines Agency,
Doc. Ref. EMEA/CHMP/410869/2006; 2008.
8. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential
of adult human mesenchymal stem cells. Science 1999, 284:143–147.
9. Mareschi K, Rustichelli D, Calabrese R, Gunetti M, Sanavio F, Castiglia S,
Risso A, Ferrero I, Fagioli F: Multipotent Mesenchymal Stromal Stem Cell
Expansion by Plating Whole Bone Marrow at a. A More Advantageous
Method for Clinical Use. Stem Cell International: Low Cellular Density; 2012.
10. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by
cultured human dendritic cells is maintained by granulocyte/
macrophage colony-stimulating factor plus interleukin 4 and
downregulated by tumor necrosis factor alpha. J Exp Med 1994,
179:1109–1118.
11. Dranoff G: GM-CSF-secreting melanoma vaccines. Oncogene 2003,
22:3188–3192.
12. Muraro M, Mereuta OM, Saglio F, Carraro F, Berger M, Madon E, Fagioli F:
Interactions between osteosarcoma cell lines and dendritic cells immune
function: An in vitro study. Cell Immunol 2008, 253:71–80.
13. Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R,
Secondino S, Schiavetto I, Caliogna L, Locatelli F, et al: Feasibility and
safety of adoptive immunotherapy with ex vivo-generated
autologous, cytotoxic T lymphocytes in patients with solid tumor.
Cytotherapy 2012, 14:80–90.
14. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining
multipotent mesenchymal stromal cells. The International Society for
Cellular Therapy position statement. England: Cytotherapy. Volume 8;
2006:315–317.
Rustichelli et al. Journal of Translational Medicine 2013, 11:197 Page 13 of 13
http://www.translational-medicine.com/content/11/1/19715. Montagna D, Schiavo R, Gibelli N, Pedrazzoli P, Tonelli R, Pagani S,
Assirelli E, Locatelli F, Pession A, Fregoni V, et al: Ex vivo generation
and expansion of anti-tumor cytotoxic T-cell lines derived from
patients or their HLA-identical sibling. Int J Cancer 2004,
110:76–86.
16. Guideline on validation of the limulus amebocyte lysate test as an end-product
endotoxin test f0r human and animal parenteral drugs, biological products,
and medical devices.department of health and human service, public health
service, food and drug administration; 1987.
17. Collino CJ, Jaldin-Fincati JR, Chiabrando GA: Statistical criteria to establish
optimal antibody dilution in flow cytometry analysis. Cytometry B Clin
Cytom 2007, 72:223–226.
18. European Parliament and Council Directive 2001/20/EC of 4 April 2001 on
the approximation of the laws, regulations and administrative provisions
of the Member States relating to the implementation of good clinical
practice in the conduct of clinical trials on medicinal products for
human use.
19. European Parliament and Council Directive: /83/EC of 2001/83/EC of 6th
November 2001 on the community code relating to medicinal products for
human use; 2001.
20. European Parliament and Council Directive: 23/EC of 31 March 2004 on
setting standards of quality and safety for the donation, procurement, testing,
processing, preservation, storage and distribution of human tissues
and cells; 2004.
21. Italian Parliament Legislative decree N.191/2007 of the to adopt EC Directive
2004/23/EC.
22. European Parliament and of the Council Regulation (EC) N. 1394/2007 of 13
November 2007 on advanced therapy medicinal products.
23. European Commission: The Rules Governing Medical Products in European
Union. Good manufacturing practices; 1997. volume 4.
24. Points to Consider on the Manufacture and Quality Control of Human Somatic
Cell Therapy Medicinal Products (EMEA CPMP/BWP/41450/98).
25. Soncin S, Lo Cicero V, Astori G, Soldati G, Gola M, Surder D,
Moccetti T, Walfish S: A practical approach for the validation of
sterility, endotoxin and potency testing of bone marrow
mononucleated cells used in cardiac regeneration in
compliance with good manufacturing practice. J Transl Med
2009, 7:78.
26. Muraro M, Mereuta OM, Saglio F, Carraro F, Cravero C, Fagioli F:
Tumor-associated-antigens or osteosarcoma cell line lysates: two
efficient methods for in vitro generation of CTLs with special regard to
MHC-I restriction. Cell Immunol 2011, 266:123–129.
27. Yoshikawa T, Yanoma S, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H,
Noguchi Y: Induction of lymphokine-activated cytotoxic T lymphocytes
stimulated by dendritic cells and autologous tumor from a patient with
gastric cancer and their effects in vitro. Hepatogastroenterology 2005,
52:289–292.
28. Kass R, Agha J, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R,
Hutchins L, Cannon MJ, Klimberg S, Santin AD: In vitro induction of tumor-
specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from
patients with locally advanced breast cancer by tumor antigen-pulsed
autologous dendritic cells. J Surg Res 2003, 112:189–197.
29. Schultze J, Nadler LM, Gribben JG: B7-mediated costimulation and the
immune response. Blood Rev 1996, 10:111–127.
30. Lechmann M, Zinser E, Golka A, Steinkasserer A: Role of CD83 in the
immunomodulation of dendritic cells. Int Arch Allergy Immunol 2002,
129:113–118.
31. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP,
Hwu P, Wang RF: Induction of CD4(+) T cell-dependent antitumor
immunity by TAT-mediated tumor antigen delivery into dendritic cells.
J Clin Invest 2002, 109:1463–1470.
32. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R,
Papamichail M: Tumor-specific CD4+ T lymphocytes from cancer patients
are required for optimal induction of cytotoxic T cells against the
autologous tumor. J Immunol 2000, 164:3902–3912.
33. Sanders ME, Makgoba MW, Shaw S: Human naive and memory T cells:
reinterpretation of helper-inducer and suppressor-inducer subsets.
Immunol Today 1988, 9:195–199.
34. Sallusto F, Geginat J, Lanzavecchia A: Central memory and effector
memory T cell subsets: function, generation, and maintenance. Annu Rev
Immunol 2004, 22:745–763.35. FDA Guidance for Industry Part 11: Electronic Records: Electronic Signatures.
Scope and Application; 2003.
36. FDA Title 21 CFR Part 11: Electronic Records; Electronic Signatures.
Final Rule; 1997.
37. Guidance for Industry Computerized Systems Used in Clinical
Investigations; 2007.
doi:10.1186/1479-5876-11-197
Cite this article as: Rustichelli et al.: Validation of analytical methods in
compliance with good manufacturing practice: a practical approach.
Journal of Translational Medicine 2013 11:197.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
